A GOLD STANDARD FOR EYE CARE DRUG DELIVERY
The Medakai™ System, featuring our flagship OcuEase™ product, is a patented, clinically validated microdose delivery platform that overcomes the most persistent challenges in ophthalmic care—patient compliance, inconsistent dosing, and limited drug penetration.
OcuEase™ delivers controlled, continuous microdoses comfortably and discreetly under the lower eyelid—offering a patient-friendly alternative to traditional eye drops, implants, and drug-eluting lenses.
KEY HIGHLIGHTS
Scalable Opportunities
Medakai™ Systems represents a platform-level opportunity in ophthalmic drug delivery, with OcuEase™ as the flagship product and lead asset, and a clear path to expand the platform into additional indications and acquisition opportunities.
• Regulatory pathway for OcuEase™• Scalable manufacturing and distribution• Multiple ophthalmic indication potential• Partnership and acquisition opportunities •
Clinical Data
[1]
Comfort & Retention
[2]
Therapeutic Flexibility
[3]
Controlled Delivery
Early clinical work highlights comfort, controlled delivery, and flexibility across indications.
Supports flexibility to address multiple ophthalmic indications within the platform.
Demonstrated continuous, controlled delivery over time in early evaluations.